NYSE: RDYDr Reddys Laboratories Ltd Stock
$71.12-0.30 (-0.42%)
Updated Apr 15, 2024
RDY Price
$71.12
Fair Value Price
N/A
Market Cap
$11.84B
52 Week Low
$53.12
52 Week High
$77.72
P/E
N/A
P/B
4.22x
P/S
3.17x
PEG
N/A
Dividend Yield
1.37%
Revenue
$2.99B
Earnings
$548.26M
Gross Margin
56.7%
Operating Margin
25.13%
Profit Margin
18.3%
Debt to Equity
0.39
Operating Cash Flow
$847M
Beta
0.48
Next Earnings
May 22, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RDY Overview
Dr. Reddy's Laboratories Limited manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary pharmaceutical products. It's generic products are indicated for the treatment of gastrointestinal disorders, various cancers, cardiovascular diseases, pain, central nervous system disorders, infectious diseases, and pediatric diseases. Its pipeline includes New Chemical Entities that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. Dr. Reddy's Laboratories was incorporated in 1984 and is headquartered in Hyderabad, India.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RDY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RDY is poor value based on its book value relative to its share price (4.22x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.03x)
P/B vs Industry Valuation
RDY's Earnings (EBIT) of $751.03M can safely cover interest payments on company debt ($163.73M)
Interest Coverage Financials
RDY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 35 more RDY due diligence checks available for Premium users.
Be the first to know about important RDY news, forecast changes, insider trades & much more!
RDY News
Valuation
RDY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
49.25x
Market
41.94x
RDY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.22x
Industry
2.03x
RDY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RDY's financial health
Profit margin
Revenue
$3.0B
Net Income
$548.3M
Profit Margin
18.3%
RDY's Earnings (EBIT) of $751.03M... subscribe to Premium to read more.
Interest Coverage Financials
RDY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.9B
Liabilities
$1.1B
Debt to equity
0.39
RDY's short-term assets ($2.52B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDY's short-term assets ($2.52B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RDY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$846.6M
Investing
-$503.3M
Financing
-$326.8M
RDY's operating cash flow ($845.76M)... subscribe to Premium to read more.
Debt Coverage Financials
RDY vs Pharmaceutical Stocks
Dr Reddys Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.